STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. This segment offers its products and services to acute care hospitals and other healthcare settings. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The company is based in Dublin, Ireland.
IPO Year:
Exchange: NYSE
Website: steris.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
2/6/2024 | $253.00 | Overweight | KeyBanc Capital Markets |
5/30/2023 | $206.00 | Equal-Weight | Morgan Stanley |
4/14/2023 | $215.00 → $197.00 | Overweight → Neutral | Piper Sandler |
9/23/2022 | Buy → Hold | Needham | |
7/14/2022 | $240.00 | Overweight | Piper Sandler |
4/7/2022 | $275.00 | Outperform | Wolfe Research |
2/14/2022 | $250.00 → $270.00 | Market Outperform | JMP Securities |
2/10/2022 | $254.00 → $263.00 | Buy | Needham |
11/4/2021 | $255.00 → $270.00 | Overweight | Stephens & Co. |
11/4/2021 | $239.00 → $256.00 | Overweight | Keybanc |
4 - STERIS plc (0001757898) (Issuer)
4 - STERIS plc (0001757898) (Issuer)
4 - STERIS plc (0001757898) (Issuer)
4 - STERIS plc (0001757898) (Issuer)
4 - STERIS plc (0001757898) (Issuer)
4 - STERIS plc (0001757898) (Issuer)
4 - STERIS plc (0001757898) (Issuer)
4 - STERIS plc (0001757898) (Issuer)
4 - STERIS plc (0001757898) (Issuer)
4 - STERIS plc (0001757898) (Issuer)
10-Q - STERIS plc (0001757898) (Filer)
8-K - STERIS plc (0001757898) (Filer)
8-K - STERIS plc (0001757898) (Filer)
11-K - STERIS plc (0001757898) (Filer)
ARS - STERIS plc (0001757898) (Filer)
DEFA14A - STERIS plc (0001757898) (Filer)
DEF 14A - STERIS plc (0001757898) (Filer)
SD - STERIS plc (0001757898) (Filer)
8-K - STERIS plc (0001757898) (Filer)
10-K - STERIS plc (0001757898) (Filer)
DUBLIN, IRELAND, May 03, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that Esther M. Alegria, Ph.D. has been elected to the Board of Directors, effective today. "We are pleased to welcome Dr. Alegria to our Board," said Mohsen Sohi, Chairman of STERIS. "She brings over three decades of experience in the biopharmaceuticals industry to our Board and will be a valuable addition." Dr. Alegria is the Founder and Chief Executive Officer of APIE Therapeutics, where she leads a team focused on the development of therapeutic drugs to treat chronic and debilitating diseases. Prior to APIE, Dr. Alegria was President and Senior Executive Advisor at Catal
David B. Lewis to retire at the Company's 2021 Annual Meeting of Shareholders Company appoints Paul E. Martin to Board DUBLIN, IRELAND, May 11, 2021 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced changes to its Board of Directors. David Lewis, Board member since 2010 has announced that he will not stand for election when his term expires on July 29, 2021. In addition, effective May 5, 2021, Paul E. Martin, former Senior Vice President and Chief Information Officer for Baxter International Inc., has been elected to the company's Board of Directors. "We are grateful for David's long-term commitment to STERIS and will miss his unique perspective. W
DUBLIN, IRELAND, Aug. 26, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will participate in the Morgan Stanley Healthcare Conference in New York City on Wednesday, September 4, 2024. Dan Carestio, President and CEO of STERIS will present at 1:50 p.m. Eastern Time. A simultaneous webcast and replay of the Company's presentation will be available on STERIS's investor relations website at www.steris-ir.com. STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life scie
Total revenue from continuing operations increased 8%; constant currency organic revenue grew 6%As reported EPS from continuing operations increased to $1.41; adjusted EPS increased to $2.03Fiscal 2025 outlook reiterated DUBLIN, IRELAND , Aug. 06, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2025 first quarter ended June 30, 2024. Total revenue from continuing operations for the first quarter of fiscal 2025 increased 8% to $1.3 billion compared with $1.2 billion in the first quarter of fiscal 2024. Constant currency organic revenue from continuing operations for the first quarter increased 6%. "We are ple
DUBLIN, IRELAND, July 31, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that the Company will distribute a quarterly interim dividend of $0.57 per share. This represents a $0.05 increase in the dividend and the Company's 19th consecutive year of dividend growth. The dividend is payable on September 20, 2024, to shareholders of record at the close of business on September 5, 2024. Additional information about the U.S. tax treatment of dividends, including required Forms 8937, is available at www.steris-ir.com. STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE H
DUBLIN, IRELAND, July 23, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2025 first quarter financial results at 9:00 a.m. ET on August 7, 2024. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing financial results will be issued after the U.S. market closes on August 6, 2024. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET on August 7, 2024,
AUSTIN, Texas, June 3, 2024 /PRNewswire/ -- An affiliate of Peak Rock Capital ("Peak Rock"), a leading middle-market private equity firm, announced today that it has completed the previously announced acquisition of the dental segment ("HuFriedyGroup" or the "Company") of STERIS plc (NYSE:STE) ("STERIS"). Founded in 1908, HuFriedyGroup is a leading global manufacturer of high-quality instruments, infection prevention products, instrument management systems, and conscious sedation products for the dental industry. The Company has industry leading brands, including Hu-Friedy, Crosstex, Omnia, and Accutron. Headquartered in Chicago, Illinois, the Company serves customers in ~100 countries, and
Total fiscal 2024 revenue increased 12% to $5.5 billionTotal fiscal 2024 U.S. GAAP earnings per diluted share of $3.81; adjusted earnings per diluted share increased to $8.83Targeted restructuring plan announced DUBLIN, IRELAND , May 08, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2024 fourth quarter ended March 31, 2024. Total revenue for the fourth quarter of fiscal 2024 increased 10% to $1.5 billion compared with $1.4 billion in the fourth quarter of fiscal 2023. Constant currency organic revenue from continuing operations for the fourth quarter increased 7% to $1.4 billion compared with $1.3 billion in
DUBLIN, IRELAND, May 01, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that the Company will distribute a quarterly interim dividend of $0.52 per share. The dividend is payable on June 26, 2024, to shareholders of record at the close of business on June 12, 2024. Additional information about the U.S. tax treatment of dividends, including required Forms 8937, is available at www.steris-ir.com. STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare, life sciences and dental product
DUBLIN, IRELAND, April 24, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2024 fourth quarter and full year financial results at 9:00 a.m. ET on May 9, 2024. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing financial results will be issued after the U.S. market closes on May 8, 2024. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET on May 9,
AUSTIN, Texas, April 11, 2024 /PRNewswire/ -- An affiliate of Peak Rock Capital ("Peak Rock"), a leading middle-market private equity firm, announced today that it has signed a definitive agreement to acquire the dental segment ("HuFriedyGroup" or the "Company") of STERIS plc (NYSE:STE) ("STERIS"). Founded in 1908, HuFriedyGroup is a leading global manufacturer of high-quality instruments, infection prevention products, instrument management systems, and conscious sedation products for the dental industry. The Company has industry leading brands, including Hu-Friedy, Crosstex, Omnia, and Accutron. Headquartered in Chicago, Illinois, the Company serves customers in ~100 countries, and is s
Transaction expected to close in STERIS's first quarter of fiscal 2025Divestiture allows STERIS to focus on Customers within core marketsProceeds primarily to be used to repay debt DUBLIN, IRELAND, April 11, 2024 (GLOBE NEWSWIRE) -- ) - STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced that the Company has entered into a definitive agreement to divest its Dental segment to Peak Rock Capital, a leading middle-market private investment firm, for $787.5 million (the "Transaction"). The Transaction is structured as an equity sale. The Transaction terms also include the opportunity for STERIS to receive an additional earnout of up to $12.5 million, subject to the achievement of
These large-cap stocks were the best performers in the last week. Are they in your portfolio? Teva Pharmaceutical Industries (NYSE:TEVA) shares surged 16.24% after the company reported mixed Q1 financial results and announced results from the efficacy portion of the Phase 3 SOLARIS trial of TEV-‘749 in adult patients with schizophrenia compared to placebo. Toast, Inc. Class A (NYSE:TOST) shares increased 14.71% on strong first-quarter 2024 financial results, with revenue of $1.075 billion, beating the estimates of $1.041 billion. Several analysts raised the price target on the stock. Applovin Corporation (NASDAQ:APP) shares were up 13.28% after the company reported better-than-expe
Piper Sandler analyst Jason Bednar reiterates Steris (NYSE:STE) with a Neutral and raises the price target from $220 to $225.
Needham analyst Mike Matson reiterates Steris (NYSE:STE) with a Hold.
JMP Securities analyst David Turkaly reiterates Steris (NYSE:STE) with a Market Outperform and maintains $265 price target.
Capital expenditures are anticipated to be approximately $360 million and free cash flow is expected to be approximately $700 million.
STERIS today is also announcing a targeted restructuring plan, which includes restructuring of the Healthcare surgical business in Europe, as well as other actions including impairment of an internally developed X-ray accelerator, product rationalizations and facility consolidations. The Company anticipates total pre-tax restructuring charges of approximately $100 million with $44.4 million recorded in the fiscal 2024 fourth quarter and the balance expected to be recorded in fiscal 2025. The restructuring plan will be excluded from adjusted earnings per diluted share. Of the $100 million charge, approximately $50 million is non-cash. EBIT improvement resulting from these actions is anticipa
Steris (NYSE:STE) reported quarterly earnings of $2.58 per share which beat the analyst consensus estimate of $2.35 by 9.79 percent. This is a 12.17 percent increase over earnings of $2.30 per share from the same period last year. The company reported quarterly sales of $1.419 billion which beat the analyst consensus estimate of $1.411 billion by 0.55 percent. This is a 2.45 percent increase over sales of $1.385 billion the same period last year.
Needham analyst Mike Matson reiterates Steris (NYSE:STE) with a Hold.
Total revenue from continuing operations increased 8%; constant currency organic revenue grew 6%As reported EPS from continuing operations increased to $1.41; adjusted EPS increased to $2.03Fiscal 2025 outlook reiterated DUBLIN, IRELAND , Aug. 06, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2025 first quarter ended June 30, 2024. Total revenue from continuing operations for the first quarter of fiscal 2025 increased 8% to $1.3 billion compared with $1.2 billion in the first quarter of fiscal 2024. Constant currency organic revenue from continuing operations for the first quarter increased 6%. "We are ple
DUBLIN, IRELAND, July 31, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that the Company will distribute a quarterly interim dividend of $0.57 per share. This represents a $0.05 increase in the dividend and the Company's 19th consecutive year of dividend growth. The dividend is payable on September 20, 2024, to shareholders of record at the close of business on September 5, 2024. Additional information about the U.S. tax treatment of dividends, including required Forms 8937, is available at www.steris-ir.com. STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE H
DUBLIN, IRELAND, July 23, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2025 first quarter financial results at 9:00 a.m. ET on August 7, 2024. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing financial results will be issued after the U.S. market closes on August 6, 2024. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET on August 7, 2024,
Total fiscal 2024 revenue increased 12% to $5.5 billionTotal fiscal 2024 U.S. GAAP earnings per diluted share of $3.81; adjusted earnings per diluted share increased to $8.83Targeted restructuring plan announced DUBLIN, IRELAND , May 08, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2024 fourth quarter ended March 31, 2024. Total revenue for the fourth quarter of fiscal 2024 increased 10% to $1.5 billion compared with $1.4 billion in the fourth quarter of fiscal 2023. Constant currency organic revenue from continuing operations for the fourth quarter increased 7% to $1.4 billion compared with $1.3 billion in
DUBLIN, IRELAND, May 01, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that the Company will distribute a quarterly interim dividend of $0.52 per share. The dividend is payable on June 26, 2024, to shareholders of record at the close of business on June 12, 2024. Additional information about the U.S. tax treatment of dividends, including required Forms 8937, is available at www.steris-ir.com. STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare, life sciences and dental product
DUBLIN, IRELAND, April 24, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2024 fourth quarter and full year financial results at 9:00 a.m. ET on May 9, 2024. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing financial results will be issued after the U.S. market closes on May 8, 2024. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET on May 9,
Third quarter revenue increases 15% as reported; 10% constant currency organicAs reported diluted earnings per share increased to $1.42; adjusted earnings per share increased to $2.22Fiscal 2024 outlook updated DUBLIN, IRELAND, Feb. 07, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2024 third quarter ended December 31, 2023. Revenue as reported for the quarter increased 15% to $1.40 billion compared with $1.22 billion in the third quarter of fiscal 2023. Constant currency organic revenue (see Non-GAAP Financial Measures) increased 10% for the third quarter of fiscal 2024 as compared to the third quarter of fisca
DUBLIN, IRELAND , Jan. 30, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that the Company will distribute a quarterly interim dividend of $0.52 per share. The dividend is payable on March 22, 2024, to shareholders of record at the close of business on February 23, 2024. Additional information about the U.S. tax treatment of dividends, including required Forms 8937, is available at www.steris-ir.com. STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare, life sciences and dental p
DUBLIN, IRELAND, Jan. 23, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that it will host a conference call to discuss its fiscal 2024 third quarter financial results at 9:00 a.m. ET on February 8, 2024. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing financial results will be issued after the U.S. market closes on February 7, 2024. For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. ET on November 8, 2
Second quarter revenue growth of 12% as reported and 8% constant currency organicAs reported diluted earnings per share increased to $1.16; adjusted earnings increased to $2.03Fiscal 2024 outlook maintained DUBLIN, IRELAND, Nov. 07, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2024 second quarter ended September 30, 2023. Revenue as reported for the quarter increased 12% to $1.34 billion compared with $1.20 billion in the second quarter of fiscal 2023. Constant currency organic revenue (see Non-GAAP Financial Measures) increased 8% for the second quarter of fiscal 2024 as compared to the second quarter of
SC 13G/A - STERIS plc (0001757898) (Subject)
SC 13G/A - STERIS plc (0001757898) (Subject)
SC 13G/A - STERIS plc (0001757898) (Subject)
SC 13G/A - STERIS plc (0001757898) (Subject)
SC 13G/A - STERIS plc (0001757898) (Subject)
SC 13G/A - STERIS plc (0001757898) (Subject)
SC 13G/A - STERIS plc (0001757898) (Subject)
SC 13G - STERIS plc (0001757898) (Subject)
SC 13G - STERIS plc (0001757898) (Subject)
SC 13G/A - STERIS plc (0001757898) (Subject)
KeyBanc Capital Markets resumed coverage of Steris with a rating of Overweight and set a new price target of $253.00
Morgan Stanley initiated coverage of Steris with a rating of Equal-Weight and set a new price target of $206.00
Piper Sandler downgraded Steris from Overweight to Neutral and set a new price target of $197.00 from $215.00 previously
Needham downgraded Steris from Buy to Hold
Piper Sandler initiated coverage of Steris with a rating of Overweight and set a new price target of $240.00
Wolfe Research initiated coverage of Steris with a rating of Outperform and set a new price target of $275.00
JMP Securities reiterated coverage of Steris with a rating of Market Outperform and set a new price target of $270.00 from $250.00 previously
Needham reiterated coverage of Steris with a rating of Buy and set a new price target of $263.00 from $254.00 previously
Stephens & Co. reiterated coverage of Steris with a rating of Overweight and set a new price target of $270.00 from $255.00 previously
Keybanc reiterated coverage of Steris with a rating of Overweight and set a new price target of $256.00 from $239.00 previously